Loading...
NUVA logo

NuVasive, Inc.Informe acción NasdaqGS:NUVA

Capitalización bursátil US$2.1b
Precio de las acciones
n/a
US$49
n/adescuento intrínseco
1Y-8.3%
7D1.5%
1D
Valor de la cartera
​
Ver

NuVasive, Inc.

Informe acción NasdaqGS:NUVA

Capitalización de mercado: US$2.1b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

NuVasive (NUVA) Resumen de Acciones

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. Saber más

Análisis fundamental de NUVA
Puntuación del snowflake
Valoración3/6
Crecimiento futuro3/6
Rendimiento pasado1/6
Salud financiera3/6
Dividendos0/6

Recompensas

Cotiza un 47.4% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 46.22%

Ha pasado a ser rentable este año

Los analistas coinciden en que el precio de las acciones subirá un 23.3%

Análisis de riesgos

La deuda no está bien cubierta por el flujo de caja operativo

Grandes partidas extraordinarias que afectan a los resultados financieros


NUVA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Competidores de NuVasive, Inc.

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del NuVasive
Precios históricos de las acciones
Precio actual de la acciónUS$39.75
Máximo en las últimas 52 semanasUS$49.53
Mínimo de 52 semanasUS$35.17
Beta1.07
Cambio en 1 mes-0.63%
Variación en 3 meses0.84%
Cambio de 1 año-8.30%
Variación en 3 años-22.24%
Variación en 5 años-42.71%
Variación desde la OPV248.68%

Noticias y actualizaciones recientes

Recent updates

Artículo de análisis • Apr 18

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Artículo de análisis • Jan 24

What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

While NuVasive, Inc. ( NASDAQ:NUVA ) might not be the most widely known stock at the moment, it saw a significant share...
Artículo de análisis • Dec 31

NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Key Insights NuVasive's estimated fair value is US$60.8 based on 2 Stage Free Cash Flow to Equity Current share price...
Artículo de análisis • Dec 05

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
Artículo de análisis • Nov 13

These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Artículo de análisis • Sep 22

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Does the September share price for NuVasive, Inc. ( NASDAQ:NUVA ) reflect what it's really worth? Today, we will...
Artículo de análisis • Sep 01

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...
Seeking Alpha • Aug 17

NuVasive Likely Undervalued, But It's Hard To Find Catalysts

NuVasive modestly exceeded topline expectations for Q2, but core U.S. growth is still soft, particularly when factoring in the above-average growth of the cervical disc business. In a challenging spine care market, NuVasive looks at risk of "drifting", with neither the above-average revenue growth nor strong core margins that med-tech investors often seek. NuVasive isn't beyond hope - the cervical franchise looks strong, Pulse is still a long-term opportunity, and NUVA still has good overall share, but it needs to be more dynamic. The shares are undervalued below the mid-$60s, but the stock badly needs a catalyst to get investors excited about the name again. Valuation alone doesn't move stocks - expensive stocks don't fall just because they're expensive, and cheap stocks don't rise just because investors suddenly decide they're too cheap. In most cases, it requires some sort of driver or catalyst to get investors to reconsider a name, and that's a challenge for NuVasive (NUVA) today. The shares of this spine-focused medical device company do look undervalued today, but they've looked undervalued for a while. Although the shares have slightly outperformed the broader medical device space since my last update and outperformed names like Alphatec (ATEC) and SeaSpine (SPNE) while recently starting to lag Globus (GMED), they still haven't done anything to celebrate over the last five years. NuVasive is salvageable, but the company's management needs to offer more than what is apparent today - investors need to have a reason to believe in growth drivers beyond the cervical portfolio and that long-awaited margin improvement will actually materialize. While this could happen, there's a real risk that "okay, but not great" growth and margins keep a lid on the share price performance at NuVasive. Second Quarter Results - A Little Better On The Topline, But Not Really Great Overall NuVasive's second quarter was, at best, "mixed" and not really the sort of quarter that's going to shift sentiment in a meaningfully positive way. Revenue rose 8% and beat expectations by close to 2%. U.S. spine ("Hardware") revenue rose 3% on improved case volumes, and that was better than the declines at Johnson & Johnson (JNJ) and Stryker (SYK) and on pace with Globus, but with the cervical portfolio growing more than 20%, there's still weakness in the core portfolio. U.S. Surgical revenue rose 6%, with improved Pulse sales offsetting a year-over-year decline in biologics, while international sales rose more than 20% in constant currency. Gross margin declined 120bp to 72.4%, missing by 80bp, and the med-tech sector is still seeing noticeable negative impacts from supply chain issues (components, shipping, et al.). Operating income declined 1%, missing by 3%, and operating margin fell 80bp to 13.1%, missing by more than 30bp. Management basically held the line on guidance, though hitting the full year target of 9% to 11% constant currency growth is going to require acceleration from here. Ongoing post-pandemic normalization and some new product introductions can support that acceleration, but the overall U.S. spine market isn't looking especially robust right now. Waiting For Something To Disrupt The Business (In A Good Way) It's been a long, frustrating wait for real momentum in NuVasive's business, and it does explain, at least in part, why these shares have been a laggard over the longer term (five-year, 10-year, and 15-year comparisons to the sector). Revenue growth over the last 15 years hasn't been bad (around 15% a year), but that growth has slowed considerably in the last five years (to the low single digits). Salesforce defections have been a recurrent problem over the years, and relative to companies like Globus, I think you can argue that NuVasive has under-innovated, and that's taking a toll on core franchises like the lateral interbody fusion business. The company was also certainly slow to recognize the importance of robotics, and with the Pulse robotic system no longer expected to achieve first-in-human use this year, that timeline is slipping further. NuVasive has also struggled to hit even its revised operating margin targets. Where the company once talked about the possibility of 25% or better operating margins (some rivals have achieved high-20%s for margins), more recently the goal has been on the order of 20%, but the company is still well short of that - operating margin was just over 13% in the second quarter, and the most bullish sell-side projections I've seen don't call for 20% margins at any point over the next five years. On the positive side, the company's cervical disc business is growing well, and I still see strong growth potential here, as NuVasive's discs are the only ones clinically proven to produce better outcomes than fusion surgery. I also believe the full Pulse platform (not just the robotic aspect, but the planning, neuromonitoring, imaging, and navigation capabilities) can be a significant growth driver, with an addressable market opportunity of around $1.5B (against expected total revenue of around $1.2B in FY'22).
Artículo de análisis • Aug 11

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Aug 03

NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M

NuVasive press release (NASDAQ:NUVA): Q2 Non-GAAP EPS of $0.47 misses by $0.09. Revenue of $310.5M (+5.3% Y/Y) beats by $4.12M.
Seeking Alpha • Jun 13

NuVasive: Industry Tailwinds More Than Fairly Priced

NuVasive has solid underpinnings as a potentially defensive play, with strengthening platform economics. Industry tailwinds also apply to the company, although it needs an above market growth pattern to adequately reward shareholders. We've priced NUVA at $49–$53 noting the stock may be fully priced at its current levels.
Artículo de análisis • Jun 01

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

In this article we are going to estimate the intrinsic value of NuVasive, Inc. ( NASDAQ:NUVA ) by estimating the...
Artículo de análisis • May 11

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Typically, we'll want...
Artículo de análisis • Apr 20

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Artículo de análisis • Mar 30

At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

NuVasive, Inc. ( NASDAQ:NUVA ), is not the largest company out there, but it saw a double-digit share price rise of...
Seeking Alpha • Mar 01

NuVasive's Turnaround Story Needs A Boost From Better Results

NuVasive managed a modest beat in Q4'21 and the initial guide for 2022 was okay, but the company needs to start showing clear evidence of market share regrowth. The core technology platform, including X360, is sound and newer opportunities like Simplify and Pulse can add meaningfully to revenue growth, but execution is a key unknown. Weak margins have challenged NuVasive for years, and this remains an important driver of earnings/cash flow and sentiment. NuVasive looks undervalued, but sentiment won't shift until the share losses reverse to share gains and there's evidence of positive operating leverage.
Artículo de análisis • Dec 28

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...
Artículo de análisis • Dec 02

Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?

NuVasive, Inc. ( NASDAQ:NUVA ), might not be a large cap stock, but it saw significant share price movement during...
Artículo de análisis • Nov 11

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Artículo de análisis • Oct 21

NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of NuVasive, Inc...
Artículo de análisis • Sep 29

Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...
Artículo de análisis • Aug 18

At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?

NuVasive, Inc. ( NASDAQ:NUVA ), is not the largest company out there, but it saw significant share price movement...
Seeking Alpha • Aug 12

NuVasive Still Getting No Love With COVID-19 And Competitive Worries

NuVasive produced its second straight quarter with a double-digit operating income beat, but in-line guidance and fears of renewed COVID-19 lockdowns seem to be weighing on the shares. New product innovation appears to be driving revenue growth, with Modulus and the cervical portfolio performing well, and Pulse about to launch. COVID-19 remains a clear short-term risk, but I believe NuVasive's opportunity to regain share and drive operating leverage is undervalued today.
Artículo de análisis • Jul 27

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Artículo de análisis • Jun 17

Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?

Today we will run through one way of estimating the intrinsic value of NuVasive, Inc. ( NASDAQ:NUVA ) by taking the...
Artículo de análisis • May 30

Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Artículo de análisis • May 12

Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All

The share price of NuVasive, Inc. ( NASDAQ:NUVA ) has increased significantly over the past few years. However, the...
Artículo de análisis • Mar 30

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Artículo de análisis • Mar 09

Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?

NuVasive, Inc. ( NASDAQ:NUVA ), might not be a large cap stock, but it received a lot of attention from a substantial...
Artículo de análisis • Feb 16

Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Artículo de análisis • Jan 26

A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)

How far off is NuVasive, Inc. ( NASDAQ:NUVA ) from its intrinsic value? Using the most recent financial data, we'll...
Artículo de análisis • Jan 05

What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?

NuVasive, Inc. ( NASDAQ:NUVA ) shareholders should be happy to see the share price up 11% in the last month. But in...

Rentabilidad de los accionistas

NUVAUS Medical EquipmentMercado US
7D1.5%4.4%1.1%
1Y-8.3%-17.9%28.7%

Rentabilidad vs. Industria: Los resultados de NUVA fueron inferiores a los de la industria US Medical Equipment, que obtuvo un rendimiento del -17.9% el año pasado.

Rentabilidad vs. Mercado: NUVA obtuvo unos resultados inferiores a los del mercado US, que fueron del 28.7% el año pasado.

Volatilidad de los precios

Is NUVA's price volatile compared to industry and market?
NUVA volatility
NUVA Average Weekly Movement3.8%
Medical Equipment Industry Average Movement8.7%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Precio estable de las acciones: NUVA no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de NUVA (4%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
19973,000Chris Barrywww.nuvasive.com

Resumen de fundamentos de NuVasive, Inc.

¿Cómo se comparan los beneficios e ingresos de NuVasive con su capitalización de mercado?
Estadísticas fundamentales de NUVA
Capitalización bursátilUS$2.08b
Beneficios(TTM)US$28.45m
Ingresos (TTM)US$1.23b
73.3x
Ratio precio-beneficio (PE)
1.7x
Ratio precio-ventas (PS)

¿Está NUVA sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de NUVA
IngresosUS$1.23b
Coste de los ingresosUS$347.50m
Beneficio brutoUS$878.73m
Otros gastosUS$850.28m
BeneficiosUS$28.45m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)0.54
Margen bruto71.66%
Margen de beneficio neto2.32%
Ratio deuda/patrimonio89.1%

¿Cómo se ha desempeñado NUVA a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2023/09/02 09:12
Precio de las acciones al final del día2023/08/31 00:00
Beneficios2023/06/30
Ingresos anuales2022/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

NuVasive, Inc. está cubierta por 28 analistas. 12 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
null nullArgus Research Company
Jeffrey JohnsonBaird
Adam FeinsteinBarclays